Valentine Andela v. American Assoc for Cancer Rese

389 F. App'x 137
CourtCourt of Appeals for the Third Circuit
DecidedJuly 26, 2010
DocketNo 10-1468
StatusUnpublished
Cited by9 cases

This text of 389 F. App'x 137 (Valentine Andela v. American Assoc for Cancer Rese) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Valentine Andela v. American Assoc for Cancer Rese, 389 F. App'x 137 (3d Cir. 2010).

Opinion

OPINION OF THE COURT

PER CURIAM.

Valentine B. Andela appeals the District Court’s order granting judgment on the pleadings to defendant The American Association for Cancer Research, and a subsequent order denying reconsideration. We have appellate jurisdiction under 28 U.S.C. § 1291. Because this appeal presents “no substantial question,” we will summarily affirm the District Court’s judgment. 3d Cir. IOP Ch. 10.6 and L.A.R. 27.4.

I.

In his amended complaint, Andela explained that he filed this pro se, in forma pauperis “action for actual damages, statutory damages, punitive damages, injunctive relief, attorney fees, and the cost of pursuing this action against the defendant for gross dereliction of duty; coercion, fraud and conspiracy to defraud; intentional infliction of emotional distress; violation of the Lanham Act § 43(a), 15 U.S.C. § 1125(a)[;] and[ ] violation of the Sherman Antitrust Act, 15 U.S.C. §§ 1, 2.” Am. Compl. ¶ 1.

Andela, a self-described physician/scientist specializing in cancer research, challenges defendant’s publication of a research paper in its journal Cancer Research. According to Andela, he collaborated with several individuals to prepare a paper on research that they had performed regarding the Epstein Barr Virus and lymphomas. Andela alleges that he was the primary author of the paper as originally conceived. However, in August 2007, “Dr[.J Andela’s original manuscript on Epstein Barr Virus MicroRNAs was plagiarized, falsified and submitted [by Andela’s former collaborators] for publication to the journal Cancer Research.” Am. Compl. ¶ 39. “With the complicity of the editors of Cancer Research, the manuscript was accepted for publication,” and the “plagiarized and falsified manuscript was subsequently published in March of 2008.” Id. ¶¶ 40, 41. Andela seeks to hold defendant liable under state and federal laws for publishing the paper as submitted by his former collaborators. Further, he challenges defendant’s refusal to publish his “letter to the editor” critiquing the paper.

*140 Defendant filed a motion for judgment on the pleadings after answering the amended complaint. Andela filed a motion for summary judgment. The District Court noted its lack of diversity jurisdiction, 1 and concluded that Andela’s two claims under federal law (the Lanham Act and the Sherman Act) must be dismissed. Because Andela conceded that the Lanham Act does not reach “communicative products” such as books or articles, the District Court dismissed that claim. The District Court held that the Sherman Act claims fail because Andela did not define the relevant market or describe the attempted monopolization. Moreover, the District Court concluded that Andela lacks standing under the antitrust laws because those laws aim to protect competition, not competitors, and the alleged injury is personal to Andela and not of the type that the antitrust laws were intended to redress. The District Court thus granted judgment on the pleadings, dismissed the two federal claims with prejudice, and dismissed .the remaining claims under state law without prejudice. After the District Court denied Andela’s timely filed motion for reconsideration, Andela timely filed this appeal.

II.

Our review is plenary of a decision to grant a motion for judgment on the pleadings. Rosenau v. Unifund Corp., 539 F.3d 218, 221 (3d Cir.2008). “‘Under Rule 12(c), judgment will not be granted unless the movant clearly establishes that no material issue of fact remains to be resolved and that he is entitled to judgment as a matter of law. In reviewing the grant of a Rule 12(c) motion, we must view the facts presented in the pleadings and the inferences to be drawn therefrom in the light most favorable to the nonmoving party.’ ” Id. (quoting Jablonski v. Pan Am. World Airways, Inc., 863 F.2d 289, 290-91 (3d Cir.1988)). We review the denial of a motion for reconsideration for abuse of discretion. Max’s Seafood Café v. Quinteros, 176 F.3d 669, 673 (3d Cir.1999).

After a careful review of the record, we discern no error in the District Court’s analysis. 2 Andela conceded before the District Court that the Lanham Act claim must fail because the Lanham Act does not apply to communicative products. See Dastar Corp. v. Twentieth Century Fox Film Corp., 539 U.S. 23, 36-37, 123 S.Ct. 2041, 156 L.Ed.2d 18 (2003). 3 In his response to the submission of this appeal for possible summary disposition, Andela focuses solely upon his Sherman Act claims. He argues that defendant engaged in antitrust activity by “conspiring in the unreasonable restraint of [Andelaj’s market activity,” and by entering into an alleged conspiracy to conduct a “sham peer review” of the published paper.

“A plaintiff asserting a Section 1 claim ... must allege four elements: (1) concerted action by the defendants; (2) *141 that produced anti-competitive effects within the relevant product and geographic markets; (3) that the concerted actions were illegal; and (4) that it was injured as a proximate result of the concerted action.” Howard Hess Dental Labs. v. Dentsply Int’l, 602 F.3d 237, 253 (3d Cir.2010) (quotation marks omitted); see also Rossi v. Standard Roofing, Inc., 156 F.3d 452, 464 (3d Cir.1998) (plaintiff has burden to show “adverse, anti-competitive effects within the relevant product and geographic markets”). Here, Andela failed, inter alia, to define the relevant market. His allegation that “[t]he relevant geographic marketplace is the world,” Am. Compl. II90, is insufficient. See, e.g., Queen City Pizza v. Domino’s Pizza, 124 F.3d 430, 436 (3d Cir.1997) (“Where the plaintiff fails to define its proposed relevant market with reference to the rule of reasonable interchangeability and cross-elasticity of demand, or alleges a proposed relevant market that clearly does not encompass all interchangeable substitute products even when all factual inferences are granted in plaintiffs favor, the relevant market is legally insufficient and a motion to dismiss may be granted.”). 4

Free access — add to your briefcase to read the full text and ask questions with AI

Related

SUBHER v. CITY OF PHILADELPHIA
E.D. Pennsylvania, 2022
HARRISON v. HARRISON
E.D. Pennsylvania, 2021
Wyman
E.D. Michigan, 2020
Accurso v. Infra-Red Services, Inc.
23 F. Supp. 3d 494 (E.D. Pennsylvania, 2014)
Trendx Enterprises, Inc. v. All-luminum Products, Inc.
856 F. Supp. 2d 661 (D. New Jersey, 2012)
Jersey Asparagus Farms, Inc. v. Rutgers University
803 F. Supp. 2d 295 (D. New Jersey, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
389 F. App'x 137, Counsel Stack Legal Research, https://law.counselstack.com/opinion/valentine-andela-v-american-assoc-for-cancer-rese-ca3-2010.